The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | How can ctDNA be used to monitor outcomes in colorectal cancer?
Michael Brian LaPelusa, MD, University of Texas MD Anderson Cancer Center, Houston, TX, comments on how circulating tumor DNA (ctDNA) can be used to evaluate the best course of treatment in patients with colorectal cancer. Numerous trials are assessing different checkpoint inhibitors over different timespans, and ctDNA with endoscopy can elucidate the appropriate length of treatment before surgery to spare patients from unnecessary treatment. Patients who have no ctDNA may additionally even be spared from surgery. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
